On July 1, international organizations aim to increase awareness and research for bronchiectasis to improve patient outcomes and healthcare access.
RT’s Three Key Takeaways:
- Global Awareness Initiative: The Forum of International Respiratory Societies (FIRS) and other organizations are marking the fifth annual World Bronchiectasis Day to improve understanding of this chronic lung disease.
- Clinical Impact: Bronchiectasis causes recurring lung infections and impaired mucus clearance due to scarred airways, affecting hundreds of thousands of people worldwide.
- Research Needs: Recent data indicates post-infective disease is the leading cause of the condition, highlighting a need for further study into regional differences in severity and outcomes.
The Forum of International Respiratory Societies (FIRS) is joining international organizations to recognize the fifth annual World Bronchiectasis Day on July 1, 2026. The initiative aims to raise global awareness, share clinical knowledge, and encourage research to reduce the burden of the disease for patients and families.
Bronchiectasis is a chronic lung disease that affects hundreds of thousands of children and adults globally. The condition is characterized by enlarged and scarred airways that prevent proper mucus clearance, leading to recurring lung infections. Common symptoms include frequent coughing with sputum production, breathlessness, tiredness, fever, chills, and chest pain, according to FIRS.
According to a 2023 study, post-infective disease is the most common cause of bronchiectasis. The data also showed that patients in central and eastern Europe experienced more severe cases, as measured by the Bronchiectasis Severity Index, and had higher rates of hospitalizations due to exacerbations compared with other regions. The study suggests further research is necessary to understand differences in patient characteristics, treatment, and outcomes across the world.
“World Bronchiectasis Day provides an important opportunity to increase awareness of a disease that can have a significant impact on patients’ quality of life,” said Guy Marks, president of FIRS. “Through global alliance, we can bring together patients, clinicians, researchers, and advocacy organizations to advance education, improve access to care, and accelerate progress in bronchiectasis research.”
As part of the observance, the international respiratory community is sharing educational resources, patient stories, and research updates. The American College of Chest Physicians (Chest) provides clinical resources to support healthcare professionals who treat patients with the condition. While there is currently no cure for bronchiectasis, FIRS stated that early detection and treatment can improve quality of life and long-term health.
